Default company panoramic image
2e8ab958 c9d9 4e9f b094 b8da3fa14c20


OXYVITA aims to revolutionize emergency medicine, introducing a safe and effective alternative to the traditional red blood cell transfusion

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location New Windsor, NY, USA
  • Currency USD
  • Employees 6
  • Website

Company Summary

OXYVITA Inc. is a biotech company that develops oxygen therapeutics and biomedical products utilizing our proprietary Zero-Link™ hemoglobin polymerization process. Our polymeric hemoglobin solution, OxyVita, is useful as a blood transfusion alternative due to its oxygen carrying function, and can dramatically reduce the need for blood donated and the risks of blood transfusions. OxyVita is intended for military and private sector use.


  • Default avatar
    Hanna Wollocko
    President and CEO

    Dr. Wollocko is a physician with specialization in internal diseases and extensive training in oncology. She has worked in hospitals, clinics and hospital blood banks, therefore being directly exposed to the need of the blood industry. She has previously owned and operated pharmaceutical contract laboratories and consulting firms. She has extensive knowledge in FDA regulation and preparation of clinical and pre-clinical studies.

  • Default avatar
    John Harrington

    Professor Harrington, a professor emeritus of chemistry, has been an expert in the field of acellular hemoglobin for the past 30 years. His expertise in the research on hemoglobin enables him to be the best candidate to serve as a liason between the Scientific and Medical Advisory Board and the Board of Directors. He served on the NIH's panel for the basic sciences in relation to questions still unresolved with blood substitutes.

  • Default avatar
    Jacek Wollocko
    COO & CIO

    Mr. Wollocko has been a consultant for the pharmaceutical industry for the past 10 years. His experience in the qualification and validation of process production equipment for FDA purposes. His role at OXYVITA is process production valiidation and adherence to CFR Part 211 compliance. Mr. Wollocko has a masters degree from SUNY New Paltz in Computer Science


  • Default avatar
    Donald A. DeSantis

Previous Investors

  • Default avatar
    ~80 individuals